Mozart Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Mozart Therapeutics's estimated annual revenue is currently $7.1M per year.
- Mozart Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Mozart Therapeutics has 46 Employees.
- Mozart Therapeutics grew their employee count by 15% last year.
Mozart Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Financial Officer | Reveal Email/Phone |
2 | VP Non-Clinical Drug Development | Reveal Email/Phone |
3 | VP, Business Operations | Reveal Email/Phone |
4 | VP, Business Operations | Reveal Email/Phone |
5 | SVP, Research | Reveal Email/Phone |
6 | VP, Finance & Admin | Reveal Email/Phone |
7 | Associate Director | Reveal Email/Phone |
8 | Associate Director | Reveal Email/Phone |
9 | Associate Director, Translational Science | Reveal Email/Phone |
10 | Chief Scientific Officer | Reveal Email/Phone |
Mozart Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.9M | 6 | 0% | N/A | N/A |
#2 | $0.9M | 6 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $5.7M | 37 | 42% | N/A | N/A |
#5 | $1.4M | 18 | -10% | N/A | N/A |
#6 | $3.7M | 48 | -21% | $16M | N/A |
#7 | $1.1M | 7 | 0% | N/A | N/A |
#8 | $0.8M | 5 | -81% | N/A | N/A |
#9 | $2.5M | 16 | -27% | N/A | N/A |
#10 | $0.8M | 5 | -17% | N/A | N/A |
What Is Mozart Therapeutics?
Founded on seminal work from leading scientists, Mozart is developing biologics to target a novel T cell network of pathogenic CD4 and cytolytic-regulatory CD8 T cells. We are taking a new approach to establish immune balance to make a meaningful difference in the lives of patients.
keywords:N/AN/A
Total Funding
46
Number of Employees
$7.1M
Revenue (est)
15%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $5.3M | 46 | 5% | N/A |
#2 | $11.9M | 46 | -13% | N/A |
#3 | $5.3M | 46 | N/A | N/A |
#4 | $5.3M | 46 | N/A | N/A |
#5 | $9.4M | 46 | 10% | $10.7M |